Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.94
+0.29 (1.67%)
Aug 15, 2025, 12:37 PM - Market open
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover Centessa Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $30.56, which forecasts a 70.39% increase in the stock price over the next year. The lowest target is $19 and the highest is $38.
Price Target: $30.56 (+70.39%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 6 | 6 | 7 | 7 |
| Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 11 | 11 | 11 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +67.27% | Aug 12, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $30 | Strong Buy | Maintains | $30 | +67.27% | Jul 30, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +67.27% | Jul 21, 2025 |
| Needham | Needham | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +95.15% | May 28, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +67.27% | May 8, 2025 |
Financial Forecast
Revenue This Year
14.03M
Revenue Next Year
n/a
from 14.03M
EPS This Year
-1.33
from -2.06
EPS Next Year
-1.55
from -1.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.8M | n/a | n/a | ||
| Avg | 14.0M | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.25 | -1.24 | -1.14 | ||
| Avg | -1.33 | -1.55 | -1.62 | ||
| Low | -1.47 | -1.77 | -2.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.